CIT Announces Key Additions to GAP Funds Investment Team

The Center for Innovative Technology (CIT), the nonprofit operations arm of the Virginia Innovation Partnership Authority (VIPA), announced that CIT GAP Funds has added two new Investment Associates to its team: Dustin Dunbar and Anthony Obi Jr. As Investment Associates, Dunbar, and Obi will support CIT GAP Funds activity including deal sourcing and due diligence activities for candidate CIT investments in high-growth technology, life science, and clean energy tech companies.

“The VIPA was created to be a catalyst for expanding innovation and entrepreneurship in Virginia. As the direct investment program of VIPA’s Investment Division, CIT GAP Funds is a key part of the Commonwealth’s strategy to leverage venture capital for Virginia-based startups,” said Robert Stolle, CEO and President, CIT. “The Commonwealth is a unique place to grow and attract technology-based businesses, and both Dustin and Anthony bring a wealth of experience relevant to CIT GAP Funds’ seed and early stage investments.”

“We are pleased to welcome Dustin and Anthony to the CIT GAP Funds team. I am confident that our new hires will play an integral role in helping the CIT GAP Funds team achieve our goals,” added Tom Weithman, Chief Investment Officer, CIT, and Managing Director, CIT GAP Funds. “The growth of our team is a reflection of the growing startup ecosystem in the Commonwealth and our continued commitment to seeding great companies. We look forward to Dustin and Anthony’s future success with CIT GAP Funds and their contributions to Virginia’s startup community.”

Dunbar brings to CIT GAP Funds a versatile background, including nine years of service as a U.S. Army Officer and experience in financial modeling, project management, funds management, business relations, and economic research. Most recently, Dunbar was Principal Associate of Operational Risk at Capital One, where he was responsible for the oversight of operational risk within the Capital Markets, Corporate Banking, and Commercial Real Estate divisions, as well as ensuring federal regulatory compliance and reporting. Previously, as Capability Development Officer for the Science and Technology Division of Combined Arms Support Command, he conducted research and valuation on emerging technologies by developing public-private relationships with both small and large businesses for contracts to develop solutions to Army problem sets. Dunbar earned his M.S. in finance from Georgetown University and his BBA in Marketing from The College of William and Mary. Dunbar will be based in CIT’s Richmond headquarters office.

Obi brings over five years of clinical and life sciences entrepreneurship experience, as well as project management and client relations skills, to the CIT GAP Funds team. Most recently, he was a fellow at DigitalDx Ventures, a woman-owned healthcare impact fund, where he supported potential investments in digital health startups. Obi was also a Venture Capital Fellow at Vencapital, a venture accelerator for underrepresented managers seeking career opportunities in venture finance, and as an Entrepreneur in Residence at U.T. Southwestern Medical Center, where he worked closely with digital health companies helping them advance their ideas from inception to commercialization. Obi began his career as founder of PreopMD, a digital health startup solving complex operating room inefficiencies. Obi holds degrees in Biology and Chemistry from Texas Southern University and is also a mentor for the Venture Mentoring Service. Obi will be based in CIT’s Northern Virginia office.

CIT GAP Funds has attracted national recognition for its contributions to the Commonwealth, enjoying recognition by C.B. Insights as Virginia’s Most Active Investor for each of the past seven years. For more details about CIT GAP Funds’ contributions to the Commonwealth of Virginia, please review the CIT GAP Funds 2020 Impact Report.

Recent News


Bio-plastics startup wins Lighthouse Labs pitch contest

Charlottsville, VA (Virginia Business) – While pitching to the sharks, entrepreneur Alec Brewer told them, “I do have white powder in my pocket,” before quickly clarifying that it wasn’t an illicit substance: “It’s PHB! It’s PHB!” The co-founder and CEO of Charlottesville-based biodegradable plastics manufacturer Ourobio, Brewer explained that his company makes PHB, or polyhydroxybutyrate,


USA FDA Grants Fast Track Designation to ReAlta Life Sciences’ Lead Compound RLS-0071

ReAlta Life Sciences (“ReAlta”), Inc., a clinical stage, rare disease company dedicated to harnessing the power of the immune system to address life threatening diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual


Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company’s Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug Dependence

New patent covers the use of the full genetic panel measuring all five genetic biomarkers CHARLOTTESVILLE, Va., — Adial Pharmaceuticals, Inc. (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11,351,154 was issued on June 7, 2022, by